View More Recent Stories
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
NeoGenomics (NEO) Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
-
NeoGenomics (NEO) 1400 contracts of April 11 calls trade
-
Neogenomics (NEO) PT Lowered to $17 at BTIG
-
Neogenomics (NEO) PT Lowered to $17 at Morgan Stanley
-
Neogenomics (NEO) PT Lowered to $18 at Needham
-
Raymond James Reiterates Market Perform Rating on Neogenomics (NEO)
-
NeoGenomics (NEO) Tops Q4 EPS by 1c; offers guidance
-
Benchmark Reiterates Hold Rating on Neogenomics (NEO) on 2025 Revenue Guidance
-
Needham Reiterates Buy Rating on Neogenomics (NEO)
-
NeoGenomics (NEO) Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
-
Adaptive Biotechnologies (ADPT) and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
-
Raymond James Reiterates Market Perform Rating on Neogenomics (NEO) 'in light of the moving parts'
-
Needham on Neogenomics (NEO): 'We view today's sell-off as an overreaction and recommend buying shares on today's weakness'
-
NeoGenomics (NEO) CEO Chris Smith to retire
-
NeoGenomics (NEO): Felicia Williams Joins NeoGenomics Board of Directors
-
BTIG Reiterates Buy Rating on Neogenomics (NEO)
-
NeoGenomics (NEO) Tops Q3 EPS by 4c, provides guidance
-
NeoGenomics (NEO) Receives New York State Approval for Neo Comprehensive Solid Tumor Test
-
Benchmark Reiterates Buy Rating on Neogenomics (NEO)
-
Needham Reiterates Buy Rating on Neogenomics (NEO)
-
NeoGenomics (NEO) Tops Q2 EPS by 3c ; Offers Guidance


